Genomictree Inc. (228760.KQ)
KRW 23550.0
(3.06%)
KRW 23550.0
(3.06%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.83 Billion KRW | -93.71% |
| 2022 | 29.17 Billion KRW | -24.1% |
| 2021 | 38.44 Billion KRW | 232.97% |
| 2020 | 11.54 Billion KRW | 862.15% |
| 2019 | 1.2 Billion KRW | 33.33% |
| 2018 | 900 Million KRW | 77.95% |
| 2017 | 505.75 Million KRW | 1.15% |
| 2016 | 500 Million KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.95 Billion KRW | 3.16% |
| 2024 Q1 | 1.89 Billion KRW | 3.13% |
| 2023 Q4 | 1.83 Billion KRW | 6.11% |
| 2023 Q3 | 1.72 Billion KRW | -80.49% |
| 2023 Q2 | 8.86 Billion KRW | -69.55% |
| 2023 Q1 | 29.1 Billion KRW | -0.27% |
| 2023 FY | 1.83 Billion KRW | -93.71% |
| 2022 Q4 | 29.17 Billion KRW | -0.07% |
| 2022 Q2 | 28.8 Billion KRW | -28.48% |
| 2022 Q1 | 40.28 Billion KRW | 4.78% |
| 2022 Q3 | 29.2 Billion KRW | 1.37% |
| 2021 Q4 | 38.44 Billion KRW | -20.45% |
| 2021 Q3 | 48.32 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| HLB Co., Ltd. | 62.7 Billion KRW | 97.074% |
| iNtRON Biotechnology, Inc. | 402.9 Million KRW | -355.352% |
| BINEX Co., Ltd. | 53.5 Billion KRW | 96.571% |
| Bioneer Corporation | 44.63 Billion KRW | 95.89% |
| Anterogen.Co.,Ltd. | 9.74 Billion KRW | 81.164% |
| MEDIPOST Co., Ltd. | 52.33 Billion KRW | 96.495% |
| CrystalGenomics, Inc. | 32 Billion USD | 94.267% |
| Helixmith Co., Ltd | 20.22 Billion KRW | 90.93% |
| Chabiotech Co.,Ltd. | 449.63 Billion KRW | 99.592% |
| Medy-Tox Inc. | 82.83 Billion KRW | 97.785% |
| Peptron, Inc. | 9.13 Billion KRW | 79.912% |
| Amicogen, Inc. | 149.59 Billion KRW | 98.774% |
| Genexine, Inc. | 67.42 Billion KRW | 97.279% |
| HLB Therapeutics Co.,Ltd. | 10.02 Billion KRW | 81.694% |
| LegoChem Biosciences, Inc. | 12.64 Billion KRW | 85.49% |
| ALTEOGEN Inc. | 83.76 Billion KRW | 97.81% |
| PharmaResearch Co., Ltd. | 34.3 Billion KRW | 94.652% |
| SillaJen, Inc. | 9.69 Billion KRW | 81.079% |
| JETEMA, Co., Ltd. | 130.49 Billion KRW | 98.594% |
| OliX Pharmaceuticals,Inc | 39.35 Billion KRW | 95.338% |
| MedPacto, Inc. | 8.6 Billion KRW | 78.677% |
| D&D Pharmatech | 8.13 Billion KRW | 77.445% |
| EASY BIO,Inc. | 82.27 Billion KRW | 97.77% |
| GI Innovation, Inc. | 3.72 Billion KRW | 50.692% |